|
Jul 1
|
Incyte Gains 9.2% in Three Months: Buy, Hold or Sell the Stock?
|
|
Jun 30
|
Jim Cramer Highlights That Incyte’s New CEO is an “Industry Veteran”
|
|
Jun 27
|
Incyte Stock Gets Relative Strength Rating Lift
|
|
Jun 27
|
Shell denies deal talks with BP, Micron reports Q3 beat: Morning Buzz
|
|
Jun 26
|
Incyte's New CEO Is A Dealmaking Machine. Will He Bring That Fervor To His New Role?
|
|
Jun 26
|
Incyte Appoints Bill Meury Chief Executive Officer; Hervé Hoppenot to Retire
|
|
Jun 24
|
How Is Incyte’s Stock Performance Compared to Other Biotech Stocks?
|
|
Jun 23
|
FDA Extends INCY's Application for Opzelura Label Expansion
|
|
Jun 23
|
5 Revealing Analyst Questions From Incyte’s Q1 Earnings Call
|
|
Jun 23
|
Q1 Rundown: Regeneron (NASDAQ:REGN) Vs Other Immuno-Oncology Stocks
|
|
Jun 20
|
Update on FDA Review of Ruxolitinib Cream (Opzelura®) for Children Ages 2-11 with Atopic Dermatitis
|
|
Jun 20
|
Incyte (INCY) Teams Up with QIAGEN to Boost Blood Cancer Diagnostic Solutions
|
|
Jun 19
|
Incyte Gets FDA Nod for the Expanded Use of Monjuvi in Lymphoma
|
|
Jun 18
|
Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma
|
|
Jun 17
|
3 Unpopular Stocks in Hot Water
|
|
Jun 16
|
Sector Update: Health Care Stocks Flat to Higher Premarket Monday
|
|
Jun 16
|
QGEN Stock Rises in After Market Following Partnership With Incyte
|
|
Jun 16
|
Qiagen and Incyte to develop diagnostic panel for myeloproliferative neoplasms
|
|
Jun 16
|
Incyte Says 86% of Blood Cancer Patients Responsive to Higher Doses of Drug Candidate
|
|
Jun 15
|
Incyte (INCY) Targets $1B Growth by 2029 with New Drug Launches
|